2026-04-17T08:01:38Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4689782026-03-28T08:47:39Zcom_2072_98col_2072_378192

Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells Álvarez Palomo, Belén Veiga, Anna Raya, Ángel Codinach, Margarita Torrents, Silvia Ponce Verdugo, Laura Rodriguez-Aierbe, Clara Cuellar, Leopoldo Alenda, Raquel Arbona, Cristina Hernández-Maraver, Dolores Fusté, Cristina Querol, Sergi Universitat Autònoma de Barcelona Hematopoietic progenitor cells Cord blood Cord blood banks Induced pluripotent stem cells HLA matching GMP manufacturing The increasing number of clinical trials for induced pluripotent stem cell (iPSC)-derived cell therapy products makes the production on clinical grade iPSC more and more relevant and necessary. Cord blood banks are an ideal source of young, HLA-typed and virus screened starting material to produce HLA-homozygous iPSC lines for wide immune-compatibility allogenic cell therapy approaches. The production of such clinical grade iPSC lines (haplolines) involves particular attention to all steps since donor informed consent, cell procurement and a GMP-compliant cell isolation process. Homozygous cord blood units were identified and quality verified before recontacting donors for informed consent. CD34+ cells were purified from the mononuclear fraction isolated in a cell processor, by magnetic microbeads labelling and separation columns. We obtained a median recovery of 20.0% of the collected pre-freezing CD34+, with a final product median viability of 99.1% and median purity of 83.5% of the post-thawed purified CD34+ population. Here we describe our own experience, from unit selection and donor reconsenting, in generating a CD34+ cell product as a starting material to produce HLA-homozygous iPSC following a cost-effective and clinical grade-compliant procedure. These CD34+ cells are the basis for the Spanish bank of haplolines envisioned to serve as a source of cell products for clinical research and therapy. The online version contains supplementary material available at 10.1186/s13287-022-02961-6. 2022 Article Stem cell research & therapy ; Vol. 13 (august 2022) open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/